Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) — Analysis Summary
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) has a market cap of $10.79B with year-over-year revenue growth of +432.1%. Net margin stands at -30.1%. The stock trades at a P/E ratio of -33.2.
Key Takeaways
- Revenue changed +432.1% year-over-year
- Net margin of -30.1%
- P/E ratio of -33.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, MDGL posted revenue growth of +432.1% and trades at a P/E of -33.2.
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -10.2x — earnings do not cover interest payments
Operating margin at -25.1% — material operating losses
Net margin at -25.3% — significant losses
The latest filing shows negative free cash flow.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
915
Headquarters
WEST CONSHOHOCKEN, PA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.